NEW YORK, July 17, 2018 /PRNewswire/ -- If you want a free Stock Review on DERM, DRNA, EGLT, and EIDX sign up now at https://stocktraderreport.com/registration/.On Monday, key US indices were mixed as the NASDAQ Composite finished the trading session down 0.26%; the Dow Jones Industrial Average edged 0.18% higher; and the S&P 500 was down 0.10%. Before the US markets open this morning, StockTraderReport.com
USA-headquartered Dermira Inc.'s stock finished Monday's session 7.18% lower at $10.73. A total volume of 1.31 million shares was traded. The Company's shares have advanced 26.24% over the previous three months. The stock is trading above its 50-day moving average by 8.05%. Furthermore, shares of Dermira, which identifies, develops, and commercializes therapies to treat dermatologic diseases, have a Relative Strength Index (RSI) of 54.05.
On June 29th, 2018, Dermira announced that the US FDA has approved Qbrexza™ (glycopyrronium) cloth, an anticholinergic indicated for the topical treatment of primary axillary hyperhidrosis in adult and pediatric patients nine years of age and older. The approval is based on results from two Phase-3 clinical trials, ATMOS-1 and ATMOS-2. Get the full research report on DERM for free by clicking below at:
Shares in USA-based Dicerna Pharmaceuticals Inc. ended at $11.92, down 4.64% from the last trading session. The stock recorded a trading volume of 256,911 shares. The Company's shares have gained 15.62% over the previous three months, 265.64% in the last twelve months, and 32.00% on an YTD basis. The stock is trading above its 200-day moving average by 15.68%. Moreover, shares of Dicerna Pharma, which focuses on the discovery and development of pharmaceuticals for the treatment of rare, viral infections; chronic liver; and cardiovascular diseases, have an RSI of 38.48.
On July 11th, 2018, Dicerna Pharma announced that the European Medicines Agency's Committee for Orphan Medicinal Products (COMP) has recommended designating DCR-PHXC, the Company's lead GalXC™ product candidate, as an orphan medicinal product for the treatment of primary hyperoxaluria in the European Union. The European Commission is expected to review the COMP opinion and issue a final ruling within 30 days of receipt. To experience our free membership services anytime/ anywhere and access the free report on DRNA, click to register at:
USA-based Egalet Corp.'s stock ended yesterday's session 4.25% lower at $0.38 with a total trading volume of 164,476 shares. The stock is trading below its 50-day moving average by 21.33%. Additionally, shares of Egalet, which develops, manufactures, and commercializes treatments for patients with pain and other conditions, have an RSI of 36.65. Join our big investor community at Stock Trader Report now and get your free report on EGLT at:
On Monday, shares in USA-headquartered Eidos Therapeutics Inc. recorded a trading volume of 147,920 shares. The stock finished the day 5.01% higher at $21.81. Shares of the Company, which focuses on developing drugs to treat diseases caused by transthyretin amyloidosis, are trading above their 50-day and 200-day moving averages by 2.74% and 2.74%, respectively.
On June 22nd, 2018, Eidos Therapeutics announced the closing of its IPO of 7,187,500 shares of common stock, including the exercise in full of the underwriters' option to purchase 937,500 additional shares of common stock, at a public offering price of $17.00 per share. The aggregate gross proceeds to the Company from the offering were approximately $122.2 million, before deducting underwriting discounts and other offering expenses.
On July 16th, 2018, research firm JP Morgan initiated an 'Overweight' rating on the Company's stock, with a target price of $36 per share. Know more about EIDX in our free research coverage at:
Stock Trader Report:
Stock Trader Report (STR) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. STR has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
STR has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third-party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email firstname.lastname@example.org. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by STR. STR is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
STR, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. STR, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, STR, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither STR nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
For any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:
Email: email@example.com Phone number: 917-979-2038Office Address: 22/F. 3 Lockhart Road, Wanchai Hong Kong
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
View original content:http://www.prnewswire.com/news-releases/pre-market-research-reports-on-biotech-stocks----dermira-dicerna-pharma-egalet-and-eidos-therapeutics-300682013.html
SOURCE Stock Trader Report
Subscribe to our Free Newsletters!